You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

CLINICAL TRIALS PROFILE FOR DOCETAXEL


✉ Email this page to a colleague

« Back to Dashboard


505(b)(2) Clinical Trials for DOCETAXEL

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Combination NCT00130520 ↗ Bevacizumab and Erlotinib Study in Advanced Ovarian Cancer Completed Genentech, Inc. Phase 2 2005-06-01 The purpose of this project is to determine if a new combination of drugs, erlotinib (Tarceva™) and bevacizumab is safe and effective for treating women diagnosed with ovarian cancer whose cancer has progressed while on prior standard chemotherapy treatment with a taxane (paclitaxel or docetaxel) and a platinum (cisplatin or carboplatin).
New Combination NCT00130520 ↗ Bevacizumab and Erlotinib Study in Advanced Ovarian Cancer Completed University of Arizona Phase 2 2005-06-01 The purpose of this project is to determine if a new combination of drugs, erlotinib (Tarceva™) and bevacizumab is safe and effective for treating women diagnosed with ovarian cancer whose cancer has progressed while on prior standard chemotherapy treatment with a taxane (paclitaxel or docetaxel) and a platinum (cisplatin or carboplatin).
New Combination NCT00251329 ↗ Docetaxel, Carboplatin, and Capecitabine as Treatment for Patients With Locally Advanced or Inflammatory Breast Cancer Before Surgery Unknown status Sanofi Phase 2 2003-05-01 The purpose of this study is to determine if this combination is safe and effective in this situation especially to increase the rate of pathological complete response (PCR). Women with large tumors and or lymph node involvement at the time of initial diagnosis may benefit from receiving chemotherapy prior to surgery to shrink the tumor and to decrease the amount of tumor involvement before surgery. If chemotherapy given before breast surgery is effective in decreasing the size of the tumor, breast conserving surgery (lumpectomy) may be possible. This new combination may be better tolerated than other commonly used regimens and, to date, appears to be at least as effective.
New Combination NCT00251329 ↗ Docetaxel, Carboplatin, and Capecitabine as Treatment for Patients With Locally Advanced or Inflammatory Breast Cancer Before Surgery Unknown status Cancer Research Network Phase 2 2003-05-01 The purpose of this study is to determine if this combination is safe and effective in this situation especially to increase the rate of pathological complete response (PCR). Women with large tumors and or lymph node involvement at the time of initial diagnosis may benefit from receiving chemotherapy prior to surgery to shrink the tumor and to decrease the amount of tumor involvement before surgery. If chemotherapy given before breast surgery is effective in decreasing the size of the tumor, breast conserving surgery (lumpectomy) may be possible. This new combination may be better tolerated than other commonly used regimens and, to date, appears to be at least as effective.
New Combination NCT00356122 ↗ Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC) Completed Genentech, Inc. Phase 2 2006-07-01 The purpose of this study was to see how well three investigational drugs worked together in preventing progression of the disease. This study provided a new combination of chemotherapy drugs - docetaxel and oxaliplatin - as first line therapy in the treatment of lung cancer. The therapy included bevacizumab that may prevent or slow down the blood supply to the tumor and may also prevent tumor growth. The three investigational drugs are United States Food and Drug Administration (FDA) approved.
New Combination NCT00356122 ↗ Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC) Completed Sanofi Phase 2 2006-07-01 The purpose of this study was to see how well three investigational drugs worked together in preventing progression of the disease. This study provided a new combination of chemotherapy drugs - docetaxel and oxaliplatin - as first line therapy in the treatment of lung cancer. The therapy included bevacizumab that may prevent or slow down the blood supply to the tumor and may also prevent tumor growth. The three investigational drugs are United States Food and Drug Administration (FDA) approved.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for DOCETAXEL

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002544 ↗ Mitoxantrone With or Without Docetaxel in Treating Women With Metastatic Breast Cancer Completed Arbeitsgemeinschaft fur Internistische Onkologie Phase 3 1993-05-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if mitoxantrone is more effective with or without docetaxel. PURPOSE: Randomized phase III trial to compare the effectiveness of mitoxantrone with or without docetaxel in treating women who have metastatic breast cancer with a poor prognosis.
NCT00002662 ↗ Paclitaxel or Docetaxel in Treating Women With Advanced Breast Cancer Completed Aventis Pharmaceuticals Phase 3 1994-08-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether paclitaxel is more effective than docetaxel for breast cancer. PURPOSE: Randomized phase III trial to study the effectiveness of paclitaxel or docetaxel in treating women with stage IIIB or metastatic breast cancer.
NCT00002707 ↗ Chemotherapy in Treating Women With Breast Cancer That Can Be Surgically Removed Completed National Cancer Institute (NCI) Phase 3 1995-12-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if chemotherapy given before surgery is more effective with or without docetaxel given before or after surgery for breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of chemotherapy using doxorubicin and cyclophosphamide with or without docetaxel in treating women who have stage II or stage III breast cancer.
NCT00002707 ↗ Chemotherapy in Treating Women With Breast Cancer That Can Be Surgically Removed Completed NSABP Foundation Inc Phase 3 1995-12-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if chemotherapy given before surgery is more effective with or without docetaxel given before or after surgery for breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of chemotherapy using doxorubicin and cyclophosphamide with or without docetaxel in treating women who have stage II or stage III breast cancer.
NCT00002775 ↗ Docetaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer Unknown status Herbert Irving Comprehensive Cancer Center Phase 1/Phase 2 1998-02-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combining docetaxel and estramustine in treating patients who have metastatic prostate cancer.
NCT00002825 ↗ Docetaxel in Treating Children With Recurrent Solid Tumors Completed National Cancer Institute (NCI) Phase 2 1997-01-01 Phase II trial to study the effectiveness of docetaxel in treating children with recurrent solid tumors. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for DOCETAXEL

Condition Name

Condition Name for DOCETAXEL
Intervention Trials
Breast Cancer 390
Prostate Cancer 265
Non-Small Cell Lung Cancer 137
Lung Cancer 111
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for DOCETAXEL
Intervention Trials
Breast Neoplasms 578
Carcinoma, Non-Small-Cell Lung 504
Prostatic Neoplasms 484
Lung Neoplasms 457
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for DOCETAXEL

Trials by Country

Trials by Country for DOCETAXEL
Location Trials
India 85
Israel 82
Switzerland 82
United States 8,354
China 774
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for DOCETAXEL
Location Trials
California 395
Texas 380
New York 374
Florida 317
Ohio 306
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for DOCETAXEL

Clinical Trial Phase

Clinical Trial Phase for DOCETAXEL
Clinical Trial Phase Trials
Phase 4 51
Phase 3 474
Phase 2/Phase 3 69
[disabled in preview] 1844
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for DOCETAXEL
Clinical Trial Phase Trials
Completed 1179
Recruiting 345
Terminated 297
[disabled in preview] 615
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for DOCETAXEL

Sponsor Name

Sponsor Name for DOCETAXEL
Sponsor Trials
National Cancer Institute (NCI) 353
Sanofi 207
Hoffmann-La Roche 88
[disabled in preview] 159
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for DOCETAXEL
Sponsor Trials
Other 2590
Industry 1497
NIH 358
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.